Bullish & Foolish
Full KTTA fundamentals All 466 on the Survival Watch

KTTAPASITHEA THERAPEUTICS CORP.

Is Pasithea Therapeutics struggling financially?

Yes, by its own account. Pasithea Therapeutics told the SEC on 13 Nov 2025, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Nov 2025

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$18.0M
Source filing
10-Q 13 Nov 2025
Balance sheet
30 Jun 2026

Cash runway

  • 15months

    If the burn speeds up

    Empty by Sep 2027

  • 22months

    If it eases off

    Empty by Apr 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$45.7M

÷

Cash burned over the last 12 months

$29.5M

What Pasithea Therapeutics told the SEC

…the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date of these financial statements. NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The Company evaluates the need to…

PASITHEA THERAPEUTICS CORP., Form 10-Q, filed 13 Nov 2025.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 617.5% share-count increase The company issued stock. Each share now owns 86.1% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 23% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt